SCHEMBL5887097

SCHEMBL5887097

COc1ccc(C2=C(Cl)C(c3ccc(Cl)cc3)=CC[CH]2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.40
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
BACE1 P56817 1/20 0.38
GLA P06280 1/20 0.37
GSK3B P49841 2/20 0.36
MAPT P10636 3/20 0.35
MAPK1 P28482 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887251 0.95 BACE1 (0.41) ALOX5RAB9ASMN1; SMN2NPC1BACE1
SCHEMBL5887070 0.90 ACHE (0.44) ALOX5RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL5887317 0.87 ALOX5 (0.39) ALOX5RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL5887134 0.87 ALOX5 (0.39) ALOX5RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL5887281 0.86 LTA4H (0.49) RAB9ASMN1; SMN2NPC1HPGDBACE1
SCHEMBL5887298 0.84 RAD51 (0.40) MAPT
SCHEMBL4811189 0.83 PTGS2 (0.38) RAB9AHPGDMAPTKDM4EMEN1
SCHEMBL5887556 0.79 ALOX5 (0.40) ALOX5RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL5887461 0.79 NPC1 (0.39) ALOX5RAB9ASMN1; SMN2NPC1HPGD
SCHEMBL5887664 0.78 ALOX5 (0.39) ALOX5RAB9ASMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ALOX5 2648/4885RAB9A 1054/4885SMN1; SMN2 1459/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ALOX5 3355/4885RAB9A 1724/4885SMN1; SMN2 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.